Evidence map›Paper›PMID 32252259›Full record

ArticleInternational journal of molecular sciences2020

Generation of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells.

Andreas Reicher, Antoneicka L Harris, Felix Prinz, Tobias Kiesslich, Miaoyan Wei, Rupert Öllinger, Roland Rad, Martin Pichler, Lawrence N Kwong

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Andreas ReicherDivision of Oncology, Medical University of Graz, Graz 8036, Austria.
Antoneicka L HarrisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Felix PrinzDivision of Oncology, Medical University of Graz, Graz 8036, Austria.
Tobias KiesslichInstitute for Physiology and Pathophysiology, Paracelsus Medical University, Salzburg 5020, Austria.
Miaoyan WeiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rupert ÖllingerInstitute of Molecular Oncology and Functional Genomics, School of Medicine, Technische Universität München, Munich 81675, Germany.
Roland RadInstitute of Molecular Oncology and Functional Genomics, School of Medicine, Technische Universität München, Munich 81675, Germany.
Martin PichlerDivision of Oncology, Medical University of Graz, Graz 8036, Austria.ORCID 0000-0002-8701-9462
Lawrence N KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USMedical University of Graz · ATTechnical University of Munich · DEParacelsus Medical University · AT

Funding

Translational Genomics and Precision Medicine in Cancer Training ProgramT32CA217789 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Subrata Sen · 2018 to 2026
$2.2M
Austrian Science Fund DK-MCD W1226, to MPAustrian Science Fund FWF W 1226Ira and Dan Schneider Foundation N/AMarshall Plan Scholarship N/AMEFOgraz - Vereinigung Forschungsförderung Med Uni Graz N/ANCI NIH HHS T32 CA217789NIH HHS 5T32CA217789-03
6 · The paper itself

Abstract

Fibroblast growth factor receptor 2 (

Indexed as

Chromosome InversionCRISPR-Cas SystemsGene EditingGene FusionCell LineChromosome BreakpointsGene TargetingGenetic LociHumansReceptor, Fibroblast Growth Factor, Type 2RNA-Binding ProteinsRNA, Guide, CRISPR-Cas SystemsBicc1 protein, humanFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2RNA-Binding ProteinsRNA, Guide, CRISPR-Cas SystemscholangiocarcinomaCRISPRFGFR2fusioninversion

Identifiers

PMID32252259
PMCPMC7178239
OpenAlexW3015002495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.